Family History Education to Improve Genetic Risk Assessment for Cancer
Principal Investigator: Maren Scheuner, MD, MPH, FACMG
Sepulveda Research Corporation
Goal: To develop, implement, and evaluate a multifaceted education program for health care providers at the Veterans Administration Greater Los Angeles Healthcare System to improve and increase the use of familial risk assessment in clinical practices for early detection of hereditary breast and ovarian cancer and hereditary nonpolyposis colorectal cancer.
Pharmacogenomics Education Program: Bridging the Gap between Science and Practice
Principal Investigator: Grace Kuo, PharmD, MPH, PhD (cand.)
University of California, San Diego
Goal: To develop an education program to increase awareness among pharmacists, pharmacy students, and other health care professionals about the validity and utility of pharmacogenomics tests and the potential benefits and harms of using these tests.
Promoting Cancer Genomics Best Practices through Surveillance, Education, and Policy
Principal Investigator: Janice Bach, MS, CGC
Michigan Department of Community Health
Goal: To engage in surveillance/monitoring, health education, and health insurance policy interventions to promote best practices and decrease morbidity and mortality from hereditary cancers in Michigan, particularly among individuals younger than 50 years of age.
Oregon Genomics Surveillance Program: Translation of Genomics
Applications into Health Practice
Principal Investigator: Katherine Bradley, PhD, RN
Oregon Department of Human Resources
Goal: To develop, implement, and evaluate a surveillance program to monitor awareness, knowledge, and use among health care providers and the public of cancer-related genomic tests and family history in Oregon. This project will also evaluate disparities associated with accessing cancer-related genetic testing and counseling.
Risk-Benefit Framework for Genetic Tests
Principal Investigator: David L. Veenstra, PhD, PharmD
University of Washington
Goal: To develop and evaluate a quantitative risk-benefit framework for new genetic tests to educate clinicians, policy makers, and other key decision makers about the potential benefits and harms of genetic testing. |